ArticleBMC pharmacology & toxicology2026
Modeling of colchicine biotransformation by COVID-19 associated Klebsiella pneumoniae: synergistic effects of cell adaptation and gamma irradiation.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicrobial biotransformation strategies for prescribed drugs have attracted great interest because the biotransformation process simulates what happens in the human metabolism and may be considered a resource for new pharmaceuticals.
methodsThe promising candidate for colchicine biotransformation was identified using Matrix-Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF/MS). Colchicine was quantified by a modified procedure based on the reduction of alkaline potassium permanganate and HPLC. Response surface methodology (RSM) was used for optimizing and modeling colchicine biotransformation. The colchicine-metabolizing products were identified using liquid chromatography-electrospray ionization-tandem mass spectrometry.
resultsFifteen bacteria infected the upper respiratory tract during the COVID-19 pandemic were collected and screened for colchicine resistance. One of them could metabolize 41.38% colchicine in enriched SF2 medium supplemented with 7gl
conclusionsThe main colchicine metabolized products; 3-(4-hydroxyphenyl) propanoic acid, 4'-hydroxy-2'-methylacetophenone, dihydrorotenone, and glabridin, potentially could be applied in the medical field for more functions than those described for the parent compound.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.